House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
Mike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer drug could be delayed another 10 months.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
Two years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the double-digit rates of growth that made it a local star.
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
Eli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests of experimental drugs up and running more quickly and efficiently.
If a biotech startup were akin to a rock band, Kristin Sherman might be the keyboardist. She’s not front-and-center on the stage, but the ballad wouldn’t be as dynamic without her pounding the chords.
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
